Literature DB >> 16864174

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.

Kenneth Villman1, Johanna Sjöström, Reino Heikkilä, Ragnar Hultborn, Per Malmström, Nils-Olof Bengtsson, Martin Söderberg, Eero Saksela, Carl Blomqvist.   

Abstract

The purpose of this study was to evaluate amplification of topoisomerase IIalpha (TOP2A) and HER2 genes as predictors of response to chemotherapy in advanced breast cancer. Gene copy number of TOP2A and HER2 were analysed with chromogenic in situ hybridization (CISH) on paraffin-embedded tissue sections from the primary tumour of 85 patients treated with anthracycline containing chemotherapy. TOP2A gene amplification was present in 14 (16%) and HER2 gene amplification in 38 (45%) of the primary tumours. Two of the 14 cases with TOP2A amplification were amplified without concurrent HER2 amplification. Neither TOP2A nor HER2 gene amplification were significantly associated with response to chemotherapy (p = 0.35 and p = 0.49, respectively).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864174     DOI: 10.1080/02841860500543182

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  14 in total

Review 1.  HER2: biology, detection, and clinical implications.

Authors:  Carolina Gutierrez; Rachel Schiff
Journal:  Arch Pathol Lab Med       Date:  2011-01       Impact factor: 5.534

Review 2.  The adjuvant treatment of HER2-positive breast cancer.

Authors:  Danijela Jelovac; Antonio C Wolff
Journal:  Curr Treat Options Oncol       Date:  2012-06

3.  Breast cancer stage prediction: a computational approach guided by transcriptome analysis.

Authors:  K Athira; G Gopakumar
Journal:  Mol Genet Genomics       Date:  2022-08-03       Impact factor: 2.980

4.  The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.

Authors:  Linbo Wang; Zhinong Jiang; Meihua Sui; Jianguo Shen; Chaoyang Xu; Weimin Fan
Journal:  BMC Cancer       Date:  2009-07-11       Impact factor: 4.430

5.  Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study.

Authors:  L G Estevez; J L Fortes; E Adrover; G Peiró; M Margel; E Castellá; J M Cuevas; L Bernet; M A Segui; X Andreu
Journal:  Clin Transl Oncol       Date:  2009-01       Impact factor: 3.405

6.  HER2/neu Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study.

Authors:  Venkataswamy Eswarachary; Imran Gorur Mohammed; Prashanth K Jayanna; Geeta V Patilokaly; Ashwini R Nargund; Gopal Krishna Dhondalay; Shilpa Prabhudesai; Rashmita Sahoo
Journal:  J Clin Diagn Res       Date:  2017-04-01

7.  Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia.

Authors:  Lionel Flamant; Annick Notte; Noelle Ninane; Martine Raes; Carine Michiels
Journal:  Mol Cancer       Date:  2010-07-13       Impact factor: 27.401

8.  Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.

Authors:  Pierre-Jean Lamy; Frédéric Fina; Caroline Bascoul-Mollevi; Anne-Claire Laberenne; Pierre-Marie Martin; L'Houcine Ouafik; William Jacot
Journal:  Breast Cancer Res       Date:  2011-02-02       Impact factor: 6.466

Review 9.  Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention.

Authors:  Melinda Csapo; Liviu Lazar
Journal:  Clujul Med       Date:  2014-08-05

Review 10.  Understanding the implications of the breast cancer pathology report: a case study.

Authors:  Susan Beikman; Patricia Gordon; Shannon Ferrari; Monica Siegel; Mary Ann Zalewski; Margaret Q Rosenzweig
Journal:  J Adv Pract Oncol       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.